DK3458594T3 - VSV/NDV hybridvira til oncolytisk terapi af cancer - Google Patents

VSV/NDV hybridvira til oncolytisk terapi af cancer Download PDF

Info

Publication number
DK3458594T3
DK3458594T3 DK17726873.7T DK17726873T DK3458594T3 DK 3458594 T3 DK3458594 T3 DK 3458594T3 DK 17726873 T DK17726873 T DK 17726873T DK 3458594 T3 DK3458594 T3 DK 3458594T3
Authority
DK
Denmark
Prior art keywords
vsv
cancer
hybrid viruses
oncolytic therapy
ndv
Prior art date
Application number
DK17726873.7T
Other languages
English (en)
Inventor
Oliver Ebert
Jennifer Altomonte
Original Assignee
Klinikum Rechts Der Isar Der Technischen Univ Muenchen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Klinikum Rechts Der Isar Der Technischen Univ Muenchen filed Critical Klinikum Rechts Der Isar Der Technischen Univ Muenchen
Application granted granted Critical
Publication of DK3458594T3 publication Critical patent/DK3458594T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/766—Rhabdovirus, e.g. vesicular stomatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK17726873.7T 2016-05-19 2017-05-18 VSV/NDV hybridvira til oncolytisk terapi af cancer DK3458594T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16170445.7A EP3246410A1 (en) 2016-05-19 2016-05-19 Vsv/ndv hybrid viruses for oncolytic therapy of cancer
PCT/EP2017/062007 WO2017198779A1 (en) 2016-05-19 2017-05-18 Vsv/ndv hybrid viruses for oncolytic therapy of cancer

Publications (1)

Publication Number Publication Date
DK3458594T3 true DK3458594T3 (da) 2021-05-31

Family

ID=56072237

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17726873.7T DK3458594T3 (da) 2016-05-19 2017-05-18 VSV/NDV hybridvira til oncolytisk terapi af cancer

Country Status (15)

Country Link
US (2) US10906942B2 (da)
EP (2) EP3246410A1 (da)
JP (1) JP6996756B2 (da)
CN (1) CN109312366B (da)
CA (1) CA3019621A1 (da)
CY (1) CY1124275T1 (da)
DK (1) DK3458594T3 (da)
ES (1) ES2865420T3 (da)
HR (1) HRP20210867T1 (da)
HU (1) HUE054799T2 (da)
LT (1) LT3458594T (da)
PL (1) PL3458594T3 (da)
PT (1) PT3458594T (da)
SI (1) SI3458594T1 (da)
WO (1) WO2017198779A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019032628A1 (en) 2017-08-07 2019-02-14 The Regents Of The University Of California GENERATING PLATFORM FOR SAFE CELLULAR THERAPEUTIC AGENTS
US20220228172A1 (en) * 2019-06-21 2022-07-21 Boehringer Ingelheim International Gmbh Novel Mechanism to Control RNA Virus Replication and Gene Expression
EP4136242A4 (en) * 2020-04-15 2024-05-22 Humane Genomics ARTIFICIAL ONCOLYTIC VIRUSES AND RELATED METHODS
CN111893097A (zh) * 2020-06-16 2020-11-06 惠君生物医药科技(杭州)有限公司 一种冠状病毒假病毒包装系统及一步法包装方法
WO2022033468A1 (zh) * 2020-08-14 2022-02-17 上海行深生物科技有限公司 水疱性口炎病毒及其治疗用途
EP3991741A1 (en) * 2020-11-02 2022-05-04 Klinikum rechts der Isar der Technischen Universität München An immune checkpoint-modulating vsv-ndv hybrid virus for oncolytic virus immonotherapy of cancer
WO2023020556A1 (zh) * 2021-08-17 2023-02-23 上海行深生物科技有限公司 病毒制剂、用于配制病毒制剂的溶液及其用途
WO2023051607A1 (zh) * 2021-09-29 2023-04-06 上海行深生物科技有限公司 病毒培养方法
CN115725658A (zh) * 2021-11-12 2023-03-03 中日友好医院(中日友好临床医学研究所) 一种新型的基于水泡性口炎病毒的crispr rna递送系统及其应用
CN114540316A (zh) * 2022-01-26 2022-05-27 上海荣瑞医药科技有限公司 溶瘤病毒及其应用
CN117065052A (zh) * 2022-05-16 2023-11-17 上海行深生物科技有限公司 递送自复制rna分子的方法
CN117402836A (zh) * 2022-07-14 2024-01-16 上海荣瑞医药科技有限公司 重组溶瘤病毒及其应用
CN115725657B (zh) * 2022-09-16 2024-06-04 中国科学院广州生物医药与健康研究院 一种节段化的水泡性口炎病毒载体及其制备方法和应用
WO2024161017A1 (en) 2023-02-02 2024-08-08 Hennrich Alexandru Adrian Avian-specific viral vaccine vectors
CN118440903A (zh) * 2024-05-10 2024-08-06 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 一种基于chNectin4基因的细胞改造方法及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
DE102008050860A1 (de) * 2008-10-08 2010-04-15 Dorothee Von Laer LCMV-GP-VSV-Pseudotypvektoren und tumorinfiltrierende Virenproduzentenzellen zur Therapie von Tumoren
EP3009145A1 (en) * 2009-03-30 2016-04-20 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof
HRP20220653T1 (hr) 2013-09-03 2022-06-24 Medimmune Limited Sastavi koji sadrže oslabljeni virus newcastleske bolesti i postupci uporabe za liječenje neoplazije

Also Published As

Publication number Publication date
CN109312366A (zh) 2019-02-05
JP2019516374A (ja) 2019-06-20
LT3458594T (lt) 2021-06-25
EP3246410A1 (en) 2017-11-22
EP3458594A1 (en) 2019-03-27
US20210221851A1 (en) 2021-07-22
PL3458594T3 (pl) 2021-09-20
EP3458594B1 (en) 2021-03-03
HUE054799T2 (hu) 2021-10-28
HRP20210867T1 (hr) 2021-07-23
US20190153039A1 (en) 2019-05-23
PT3458594T (pt) 2021-06-03
CN109312366B (zh) 2024-10-22
CY1124275T1 (el) 2022-07-22
US10906942B2 (en) 2021-02-02
WO2017198779A1 (en) 2017-11-23
JP6996756B2 (ja) 2022-02-04
SI3458594T1 (sl) 2021-08-31
CA3019621A1 (en) 2017-11-23
ES2865420T3 (es) 2021-10-15

Similar Documents

Publication Publication Date Title
DK3458594T3 (da) VSV/NDV hybridvira til oncolytisk terapi af cancer
DK3400293T4 (da) Modificeret onkolytisk virus
IL280459A (en) Phosphoramidates for the treatment of hepatitis B virus
MA46904A (fr) Administration virale de néo-antigènes
DK3552615T3 (da) Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
EP3490574B8 (en) Expression of pten-long with oncolytic viruses
DK3169340T3 (da) Kombination af onkolytisk virus med immun-checkpoint-modulatorer
ZA201900156B (en) Phosphoramidates for the treatment of hepatitis b virus
DK3439635T3 (da) Formuleringer til behandling af fast tumor
DK3213084T4 (da) Fremgangsmåde til berigelse af cirkulerende tumor dna
DK3189082T3 (da) Anti-pd-l1-konjugater til behandling af tumorer
DK3036258T3 (da) Immunreceptormodulering til behandling af cancer og virusinfektioner
DK3083970T4 (da) Fremgangsmåde til oprensning af kappebærende virusser eller virale vektorer
DK3622953T3 (da) Kombinationsbehandling af cancer
DK3198009T3 (da) Onkolytiske tumorvira og anvendelsesfremgangsmåder
DK3436074T3 (da) Thiazolidforbindelser til behandling af virale infektioner
DK3117216T3 (da) Fremgangsmåde til detektering af en solid tumor-cancer
SG10201913958QA (en) Modulation of hepatitis b virus replication
DK3468604T3 (da) Farmaceutiske kombinationer til behandling af cancer
EP3488005A4 (en) TARGETING ONCOLYTIC VIRUSES STAT3
DK3532076T3 (da) Immunterapeutiske behandlinger af tumorer
DK3137078T3 (da) Behandling af hepatitis delta-virusinfektion
DK3129037T3 (da) Onkolytiske koppevirusvektorer
EP3515462A4 (en) METHOD FOR TARGETING ONCOLYTIC VIRUSES IN TUMORS
GB201816547D0 (en) Oncolytic virus for the treatment of cancer